Reed Jobs would rather talk about curing cancer than his last name
When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in r
The fact that Reed Jobs, son of Steve Jobs, is focusing on curing cancer rather than his last name is significant in the tech industry. This shift in focus indicates a growing interest in applying technology to solve real-world problems, particularly in the field of biotech. With his firm Yosemite, Jobs is part of a larger movement of tech investors and entrepreneurs who are turning their attention to healthcare and biotechnology.
As the biotech industry continues to evolve, it's likely that we'll see more tech investors and entrepreneurs like Jobs getting involved in the space. The fact that a cluster of blockbuster drugs are losing patent protection also presents opportunities for new players to enter the market and develop innovative treatments. This could lead to a surge in investment and innovation in the biotech sector, which could have a significant impact on the tech industry as a whole.
What's worth watching next is how Yosemite and other biotech-focused venture firms navigate the complex and highly regulated world of healthcare. As these firms develop new treatments and technologies, they'll need to work closely with regulators, researchers, and healthcare providers to bring their products to market. It will be interesting to see how the tech industry's focus on speed and innovation intersects with the more cautious and rigorous approach of the healthcare sector, and what kinds of breakthroughs and challenges emerge as a result.
Originally reported by techcrunch.com. TechNews adds analysis for technology readers.